Formycon, Klinge Gain UK Approval for Eylea Biosimilar Under Brand Name Ahzantive

German companies Formycon and Klinge Biopharma announced Feb. 25 that the UK’s Medicines and Healthcare Products Regulatory Agency had granted marketing authorization for their Eylea biosimilar under the brand name Ahzantive.

The biosimilar is approved to treat wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, and macular edema following retinal vein occlusion.

Israel’s Teva Pharmaceuticals will market Ahzantive in the UK. Teva is already marketing Formycon’s ranibizumab biosimilar known as Ongavia in the UK. That biosimilar is sold in the US by Sandoz as Cimerli.

Ahzantive, also known as Baiama, was approved in Europe in January 2025. The US FDA approved Ahzantive (aflibercept-mrbb) in June 2024, but it has been blocked in the US market thanks to legal challenges from Eylea maker Regeneron.